EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinoma

Maria Perez-Lanzon, Vincent Carbonnier, Pierre Cordier, Fatima Domenica Elisa De Palma, Adriana Petrazzuolo, Christophe Klein, Floriane Arbaretaz, Khady Mangane, Gautier Stoll, Isabelle Martins, Helene Fohrer Ting, Juliette Paillet und 10 weitere

Journal for ImmunoTherapy of Cancer · 2023-06 · 11 (6) · e007117

DOI: 10.1136/jitc-2023-007117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 21.06.2023. Verfasst von Maria Perez-Lanzon und 21 weiteren Autor:innen. Beteiligte Einrichtung: Team "Metabolism, Cancer & Immunity", Centre de Recherche des Cordeliers, UMRS 1138, Inserm, Université Paris Cité, Sorbonne Université, Paris, Franc…. Hauptthemen laut MEDLINE: Progesterone, Carcinoma. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Progress in breast cancer (BC) research relies on the availability of suitable cell lines that can be implanted in immunocompetent laboratory mice. The best studied mouse strain, C57BL/6, is also the only one for which multiple genetic variants are available to facilitate the exploration of the cancer-immunity dialog. Driven by the fact that no hormone receptor-positive (HR + ) C57BL/6-derived mammary carcinoma cell lines are available, we decided to establish such cell lines.

Methods

BC was induced in female C57BL/6 mice using a synthetic progesterone analog (medroxyprogesterone acetate, MPA) combined with a DNA damaging agent (7,12-dimethylbenz[a]anthracene, DMBA). Cell lines were established from these tumors and selected for dual (estrogen+progesterone) receptor positivity, as well as transplantability into C57BL/6 immunocompetent females.

Results

One cell line, which we called B6BC, fulfilled these criteria and allowed for the establishment of invasive estrogen receptor-positive (ER + ) tumors with features of epithelial to mesenchymal transition that were abundantly infiltrated by myeloid immune populations but scarcely by T lymphocytes, as determined by single-nucleus RNA sequencing and high-dimensional leukocyte profiling. Such tumors failed to respond to programmed cell death-1 (PD-1) blockade, but reduced their growth on treatment with ER antagonists, as well as with anthracycline-based chemotherapy, which was not influenced by T-cell depletion. Moreover, B6BC-derived tumors reduced their growth on CD11b blockade, indicating tumor sustainment by myeloid cells. The immune environment and treatment responses recapitulated by B6BC-derived tumors diverged from those of ER + TS/A cell-derived tumors in BALB/C mice, and of ER – E0771 cell-derived and MPA/DMBA-induced tumors in C57BL/6 mice.

Conclusions

B6BC is the first transplantable HR + BC cell line derived from C57BL/6 mice and B6BC-derived tumors recapitulate the complex tumor microenvironment of locally advanced HR + BC naturally resistant to PD-1 immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProgesteroneCarcinomaMiceFemaleAnimalsEpithelial-Mesenchymal TransitionMice, Inbred BALB CMice, Inbred C57BLCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

Breast NeoplasmsImmunityImmunocompetenceImmunotherapyTumor Microenvironment

Substanzen

Progesterone

Autor:innen und Institutionen

  • Team "Metabolism, Cancer & Immunity", Centre de Recherche des Cordeliers, UMRS 1138, Inserm, Université Paris Cité, Sorbonne Université, Paris, France.
  • Gustave Roussy Institute, Villejuif, France.
  • Team 'Proliferation, Stress and Liver Physiopathology', Centre de Recherche des Cordeliers, Paris, France.
  • Department of Molecular Medicine and Medical Biotechnologies, University of Napoli Federico II, Napoli, Italy.
  • Centre d'Histologie, d'Imagerie cellulaire et de Cytométrie (CHIC), Centre de Recherche des Cordeliers, Paris, France, UMRS1138, Inserm, Université Paris Cité, Sorbonne Université, Paris, France.
  • Team 'Personalized medicine, pharmacogenomics, therapeutic optimization', Centre de Recherche des Cordeliers, Paris, France.

ORCID-Profile: Jonathan Pol, Maria Chiara Maiuri

Zitieren

APA

Perez-Lanzon, M., Carbonnier, V., Cordier, P., De Palma, F. D. E., Petrazzuolo, A., Klein, C., Arbaretaz, F., Mangane, K., Stoll, G., Martins, I., Fohrer Ting, H., Paillet, J., Mouillet-Richard, S., Le Corre, D., Xiao, W., Sroussi, M., Desdouets, C., Laurent-Puig, P., Pol, J., …, & Kroemer, G. (2023). New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinoma. Journal for ImmunoTherapy of Cancer, 11(6), e007117. https://doi.org/10.1136/jitc-2023-007117

Vancouver

Perez-Lanzon M, Carbonnier V, Cordier P, De Palma FDE, Petrazzuolo A, Klein C, et al. New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinoma. Journal for ImmunoTherapy of Cancer. 2023;11(6):e007117. doi:10.1136/jitc-2023-007117

BibTeX
@article{PerezLanzon2023,
  author = {Perez-Lanzon, Maria and Carbonnier, Vincent and Cordier, Pierre and De Palma, Fatima Domenica Elisa and Petrazzuolo, Adriana and Klein, Christophe and Arbaretaz, Floriane and Mangane, Khady and Stoll, Gautier and Martins, Isabelle and Fohrer Ting, Helene and Paillet, Juliette and Mouillet-Richard, Sophie and Le Corre, Delphine and Xiao, Wenjjin and Sroussi, Marine and Desdouets, Chantal and Laurent-Puig, Pierre and Pol, Jonathan and Lopez-Otin, Carlos and Maiuri, Maria Chiara and Kroemer, Guido},
  title = {New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {6},
  pages = {e007117},
  doi = {10.1136/jitc-2023-007117}
}
Kostenlos starten →